Frei A, Steffen T, Gasser M, Kümmerle U, Stierli M, Dobler-Mikola A, Gutzwiller F, Uchtenhagen A
HealthEcon AG, Basel.
Soz Praventivmed. 1998;43(4):185-94. doi: 10.1007/BF01349248.
In the 1994-1996 trial of medically controlled prescription of narcotics to dependent users, 800 places were ascribed to heroin substitutes and another 200 for methadone and morphine substitutes. The trial was evaluated with the aid of an accompanying research. Among the results demonstrated in the evaluation was an improvement of the health of the participants. The economic assessment was drawn from observations of health effects within a sub-sample of 142 participants from four centers. In a retrospective statistical survey, for each acute illness which could be influenced through the trial, the number of diagnoses was recorded in the first and thirteenth month after study entry. Also, based on a number of representative cases for each of these acute illnesses, the resource use, i.e. the types and numbers of medical products and services rendered to the patients, was recorded. The results showed a clear decline in depressive episodes, skin diseases, digestive system disorders as well as epileptic attacks and intoxication. Treatment costs could be reduced from a total of CHF 94875.--to CHF 21,998.--/month or from CHF 22.27 to CHF 5.15/patient per day. The improvement of somatic and psychic health due to the medically controlled prescription of narcotics resulted in a benefit of CHF 17.11/person per day.
在1994年至1996年对依赖毒品者进行医学控制的麻醉药品处方试验中，800个名额分配给海洛因替代品，另外200个名额用于美沙酮和吗啡替代品。该试验借助一项配套研究进行评估。评估结果显示参与者的健康状况有所改善。经济评估是根据对来自四个中心的142名参与者子样本的健康影响观察得出的。在一项回顾性统计调查中，对于每一种可通过该试验受到影响的急性疾病，记录研究开始后第一个月和第十三个月的诊断数量。此外，基于这些急性疾病中每一种的一些代表性病例，记录资源使用情况，即提供给患者的医疗产品和服务的类型和数量。结果显示抑郁发作、皮肤病、消化系统疾病以及癫痫发作和中毒明显减少。治疗费用可从每月总计94875瑞士法郎降至21998瑞士法郎，或从每人每天22.27瑞士法郎降至5.15瑞士法郎。因医学控制的麻醉药品处方而带来的身体和精神健康改善，使每人每天受益17.11瑞士法郎。
